Trials / Unknown
UnknownNCT05060822
Phase ll Study of HEC585 in Patients With IPF
A Phase II, Multi-center, Randomized, Placebo-controlled (Double-blind Design), Active Comparator-controlled (Open-label Design), Parallel-group, Dose-finding Study, to Evaluate the Efficacy and Safety of HEC585 Tablets in Patients With IPF
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 270 (estimated)
- Sponsor
- Sunshine Lake Pharma Co., Ltd. · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A Phase ll Study to evaluate the efficacy and safety of various doses of HEC585 Tablets in patients with idiopathic pulmonary fibrosis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HEC585 | HEC585 Tablets，once daily |
| DRUG | Pirfenidone | Pirfenidone，three times a day |
| DRUG | Placebo | Placebo，once daily |
Timeline
- Start date
- 2021-06-30
- Primary completion
- 2024-05-10
- Completion
- 2025-05-11
- First posted
- 2021-09-29
- Last updated
- 2023-08-18
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05060822. Inclusion in this directory is not an endorsement.